Publications by authors named "Helen Rees"

We profiled a large heterogenous cohort of matched diagnostic-relapse tumour tissue and paired plasma-derived cell free DNA (cfDNA) from patients with relapsed and progressive solid tumours of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intra-tumour heterogeneity captured by the latter, if sufficient circulating tumour-derived DNA (ctDNA) was present. Serial tumour sequencing identified putative drivers of relapse, with alterations in epigenetic drivers being a common feature.

View Article and Find Full Text PDF

Background: The World Health Organization has endorsed single-dose human papillomavirus (HPV) vaccination, but data on the impact on HPV prevalence in high HIV burden settings are limited.

Methods: A single-dose bivalent HPV vaccine was delivered to adolescent girls in grade 10 in a schools-based campaign in 1 district in South Africa. Impact on HPV 16 and 18 prevalence was evaluated using repeat cross-sectional surveys.

View Article and Find Full Text PDF
Article Synopsis
  • In 2014, South Africa launched an HPV vaccination program for girls aged 9 and older, but this study focused on 17-18 year old girls who weren't vaccinated, assessing HPV prevalence and related risk factors.
  • From June to December 2019, the study surveyed adolescents at primary care clinics and collected data on HPV testing, HIV status, and sexual history from 900 participants, with a focus on understanding the link between these factors and HPV detection.
  • Results showed that 56.5% had high-risk HPV, with a higher prevalence in those living with HIV, underscoring the need for increased HPV vaccination efforts in populations with high HIV rates.
View Article and Find Full Text PDF

We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to fill the gap in published information regarding brachytherapy for pediatric rhabdomyosarcoma and to establish guidelines for its use.*
  • An expert panel, consisting of 24 professionals in pediatric oncology and related fields, gathered to discuss their experiences and review relevant data to inform their findings.*
  • The panel concluded that brachytherapy is often used alongside tumor removal and developed consensus guidelines that will inform future research and treatment practices for this type of cancer.*
View Article and Find Full Text PDF

The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described.

View Article and Find Full Text PDF

As of November 2023, 140 World Health Organization (WHO) member states had introduced human papillomavirus (HPV) vaccination in their routine immunization schedules. Despite a continuously increasing demand from countries across all income groups, supply constraints, COVID-19 pandemic disruptions, and other factors have slowed the pace of introduction, particularly in low-resource settings. Using a population-based forecasting methodology and leveraging the WHO's yearly vaccine supply data collection, we updated global demand and supply projections for the HPV vaccine for the period of 2022-2031.

View Article and Find Full Text PDF

Background: We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.

View Article and Find Full Text PDF

Segmentina nitida Müller 1774 is a freshwater snail which was formerly widespread throughout England and south Wales. Since the 1840s it has seen a rapid decline in its range which has been attributed to deteriorating water quality due to nutrient enrichment, lowering of water tables and over-management of the ditches in which it resides. S.

View Article and Find Full Text PDF

Cipangopaludina chinensis Gray 1833 is an East Asian freshwater snail and invasive species in many parts of the world (Global Invasive Species Database, 2022). Within the UK, it was first found at the Pevensey Levels, Sussex, and has since been reported at a second site at Southampton Common, Hampshire. Both sites are designated as Sites of Special Scientific Interest (SSSI) for their wildlife importance.

View Article and Find Full Text PDF

The burden of cervical cancer is disproportionately distributed globally, with the vast majority of cases occurring in low- and middle-income countries. Women with human immunodeficiency virus (HIV) (WWH) are at increased risk of human papillomavirus (HPV) infection and cervical cancer as compared to HIV-negative individuals. HPV vaccination remains a priority in regions with a high burden of cervical cancer and high HIV prevalence.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple antiretroviral agents have shown effectiveness for HIV pre-exposure prophylaxis (PrEP), leading to a shift from placebo to active-controlled trials, which can't fully estimate efficacy without comparisons to non-use.
  • The study compared active-controlled data from a trial of injectable cabotegravir (CAB-LA) against daily oral FTC/TDF, using external trials to create counterfactual placebo estimates and assess efficacy against no intervention.
  • Results indicated that CAB-LA provided a 93%-94% risk reduction compared to placebo, while FTC/TDF showed a risk reduction of 39%-40% based on observed adherence in the study.
View Article and Find Full Text PDF
Article Synopsis
  • * The World Health Organization (WHO) started a plan in 2018 to help eliminate cervical cancer by providing vaccines, screening, and treatment.
  • * There are still big challenges in helping women with HIV, including the need for better vaccines and addressing issues like poverty and discrimination.
View Article and Find Full Text PDF

This Review initiates a wide-ranging discussion over 2023 by selecting and exploring core themes to be investigated more deeply in papers submitted to the Special Issue on the "Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs". To tackle the SARS-CoV-2 pandemic, an acceleration of vaccine development across different technology platforms resulted in the emergency use authorization of multiple vaccines in less than a year. Despite this record speed, many limitations surfaced including unequal access to products and technologies, regulatory hurdles, restrictions on the flow of intellectual property needed to develop and manufacture vaccines, clinical trials challenges, development of vaccines that did not curtail or prevent transmission, unsustainable strategies for dealing with variants, and the distorted allocation of funding to favour dominant companies in affluent countries.

View Article and Find Full Text PDF
Article Synopsis
  • Broadly protective coronavirus vaccines are essential for fighting off future versions of SARS-CoV-2 and other novel coronaviruses, helping to reduce the impact of potential outbreaks.
  • The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is a structured plan funded by major foundations, created through collaboration among experts, and outlines vital research areas and strategic goals.
  • Organized into five key topics, the CVR includes 20 goals and 86 R&D milestones, with 26 identified as high priority, to help direct funding and research efforts in making effective vaccines.
View Article and Find Full Text PDF

Introduction: In 2016, South Africa (SA) initiated a national programme to scale-up pre-exposure prophylaxis (PrEP) among female sex workers (FSWs), with ∼20,000 PrEP initiations among FSWs (∼14% of FSW) by 2020. We evaluated the impact and cost-effectiveness of this programme, including future scale-up scenarios and the potential detrimental impact of the COVID-19 pandemic.

Methods: A compartmental HIV transmission model for SA was adapted to include PrEP.

View Article and Find Full Text PDF

Plants have evolved a highly sophisticated immune system to resist pathogen attack comprising both preformed and inducible mechanisms. Over the last 50 years, various biological and chemical inducers have been used to artificially trigger the defense response in plants, thereby promoting an induced resistance (IR) to subsequent pathogen attack. IR has proven effective for disease control in laboratory and glasshouse conditions but has seldom equalled the level of protection offered by synthetic pesticides in the field.

View Article and Find Full Text PDF

Background: National advisory panels (NAPs) have been established for the care of children and young people (CYP) with cancer in the United Kingdom since 2011, with an increase in panel number in recent years. Their practice has not previously been reviewed; therefore, we sought to evaluate the role, practice and impact of six selected NAPs offering expertise in ependymoma, histiocytosis, leukaemia, neuroblastoma, renal tumours and sarcoma.

Procedure: This service evaluation used mixed methodology, including review of NAP documentation, semi-structured interviews with the NAP chairs and an analysis of the cases referred for discussion.

View Article and Find Full Text PDF

Objectives: After South Africa's second wave of COVID-19, this study estimated the SARS-CoV-2 seroprevalence among pregnant women in inner-city Johannesburg, South Africa.

Methods: In this cross-sectional survey, 500 pregnant women who were non-COVID-19-vaccinated (aged ≥12 years) were enrolled, and demographic and clinical data were collected. Serum samples were tested using the Wantai SARS-CoV-2 spike antibody enzyme-linked immunosorbent assay and Roche Elecsys® anti-SARS-CoV-2 nucleocapsid antibody assays.

View Article and Find Full Text PDF